Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy (Nimotuzumab)
A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence
Sponsor: Fudan University
A PHASE2/PHASE3 clinical study on Esophageal Squamous Cell Carcinoma, this trial is ongoing. The trial is conducted by Fudan University and has accumulated 4 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
- RenJi Hospital
- Shanghai Chest Hospital
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .